Nektar Therapeutics (NASDAQ:NKTR) just reported results for the first quarter of 2024.
- Nektar Therapeutics reported earnings per share of -19 cents. This met the analyst estimate for EPS of -19 cents.
- The company reported revenue of $21.64 million.
- This was 41.06% better than the analyst estimate for revenue of $15.34 million.